Real-Time Assessment of Homologous Recombination Deficiency During Ovarian Cancer Treatment
Technical Report,01 Jul 2017,30 Jun 2018
University of Washington Seattle United States
Pagination or Media Count:
Patients with ovarian cancer generally have a good response to this therapy, but most cancers eventually reappear and require additional rounds of chemotherapy. Precision medicine uses individual characteristics of a specific cancer to help choose the best therapy for that patient. Many ovarian cancers have defects in DNA repair that make them vulnerable to specific types of chemotherapy as well as a new class of drugs called PARP inhibitors. Over time the cancer changes and develops resistance to these therapies. Choosing the best treatment could require repeated painful and expensive biopsies in order to identify changes in the cancer that impact response to therapy. We propose to develop a blood test to monitor tumor characteristics in real-time by evaluating free-floating tumor DNA called cell-free DNA in the bloodstream. This novel assay will use cell free DNA to evaluate DNA repair alterations in ovarian cancers and how those change during the course of treatment. We hope these studies will lead to new, less invasive ways of providing ongoing tumor information that will facilitate monitoring women with ovarian cancer and choosing the therapies most likely to be effective.
- Medicine and Medical Research